Long-term results of Nivolumab + Cabozantinib in RCC

Published Date: 08 Mar 2023

The combination of first-line nivolumab and cabozantinib continues to outperform sunitinib in the treatment of patients with advanced renal cell carcinoma (RCC).

Read Full News

Latest News



Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Study sheds light on challenges for women of color after breast cancer surgery

2.

FDA Panel Supports More Clarity in NSCLC Perioperative Immunotherapy Trials

3.

Making informed decisions and managing regret after prostate cancer treatment

4.

What Comes After Cancer?

5.

Q&A: When will individuals be able to receive customized cancer vaccines?


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot